Boston, MA - USA - Novotech, the leading Asia Pacific centred b
Chicago, IL USA - Novotech, the leading Asia Pacific centred biotech CRO is spon
Sydney, Australia - Novotech, the leading Asia Pacific centred biotech CRO condu
Asia accounted for more than 40% of the world's Non-Hodgkin Lymphoma incidence in 2020, with China contributing the majority.
Asia particularly Australia and New Zealand show the highest incidence rates of Crohn's Disease, while East Asia has shown a rising trend in both incidence and prevalence since 2015.
Kari Abitbol: Hi, everyone.
Dr. Peter Paul Yu:
The Background Early clinical-stage US biotech DiaMedica engaged Novotech to provide CRO services and help it take advantage o
The global market for pharmaceuticals is expected to reach over $1 trillion by 2024, driven by an aging population and the increasing prevalence of chronic diseases.
Asia Pacific had the fastest five-year growth rate compared to rest of the world in RNA therapy trials with the regio
Chicago
Boston
Novotech’s Medical and Regulatory Consulting team offers full range of pre-clinical, regulatory affairs support, medical and pharmacovigilance consulting services.
Novotech relies on years of experience, in-country knowledge and real-life big data to identify and propose the best-performing sites for your study.
Australia is a preferred destination for early phase trials because of simple and fast regulatory stream and lucrative R&D cash refund scheme.
Novotech’s streamlined and integrated clinical trial services are delivered by a dedicated team of professionals with deep industry and therapeutic area expertise across all phases of clinical development.
Delivering accurate, high-quality and timely biostatistics in clinical trials services, including statistical planning, analysis and reporting.
How virtual clinical trials can offer patient retention and cost benefits compared to traditional trials.
Accelerating patient recruitment and drug development with real world data (RWD)
Our bioanalytical services assist our customers in every stage of their molecule development.
Our MISSION is to create career development opportunity for everyone.
The landscape of Oncology in Asia-Pacific Biotechnology companies are facing increased challenges around participant recruitment and retention, lengthy timeframes and relatively high cost
Our team can assist in all clinical study phases and in study designs ranging from first in human, single ascending dose, multiple ascending dose, drug-drug interaction, bioavailability/bioequivalence, food effect and special population studies.
Novotech Drug Development Consulting is a full-service global product development and strategic regulatory group, providing comprehensive “lab to launch” program development services.
Novotech initiated the first national, privately owned, commercial Institutional Biosafety Committee (IBC) in Australia, successfully accredited by the Australian Office of the Gene Technology Reg
The landscape of Liver diseases in Asia-Pacific Biotechnology companies consider locations in the Asia-Pacific region, such as South Korea and China to access vast treatm
Providing Infectious diseases services and Vaccines CRO services Many biotechnology companies look at the Asia-Pacific region for their trials in Infectious diseases and Vaccines due to t
Landscape of Rare and Orphan diseases in Asia-Pacific There may be as many as 8,000 rare diseases, affecting between 6% and 8% of the worldwide population in total.
Many biotechnology companies come to Australia to conduct early phase clinical trials and take advantage of straightforward regulatory streams and of the lucrative 43.5% R&D cash refund scheme.
Global
China
